Home > Boards > US Listed > Biotechs > EDGE THERAPEUTICS (EDGE)

EDGE 0.43 +8.4% REVERSE MERGER can kick in

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
l2 hunter Member Profile
Member Level 
Followed By 3,962
Posts 152,474
Boards Moderated 2
Alias Born 02/21/11
160x600 placeholder
l2 hunter Member Level  Friday, 01/25/19 02:54:18 PM
Re: mikeo56 post# 1466
Post # of 1507 
EDGE 0.43 +8.4% REVERSE MERGER can kick in any day now imho Read >>>>>>>>>>>>>>>>>>>>>>>>> based on this News EDGE a timebomb for a huge gap and fly multi $ if R/M News above finaly close coming next days/week. i think 500% - 1000% pop possible then. hope R/M coming. then we have a jackpot i think

Therapeutics, Privately Held PDS Biotech Announce Reverse Merger

What Happened
Edge Therapeutics announced its intention to merge with the privately held, clinical-stage cancer immunotherapy company PDS Biotechnology Corp. The boards of both companies approved the proposed transaction, the companies said in a joint press release.

A reverse merger deal is a transaction in which an active private company merges with a dormant public company in a bid to go public without having to go through the arduous route of a traditional initial public offering.

Edge announced a comprehensive review of strategic alternatives in April in a bid to maximize shareholder value. The decision followed a failed late-stage trial of its aneurysmal subarachnoid hemorrhages treatment candidate, which subsequently forced the company to announce layoffs.

Why It's Important
Edge sees the merger as facilitating the creation of a publicly traded immuno-oncology company that develops novel products to treat early- and late-stage cancer.

PDS Biotech's lead candidate PDS101 has demonstrated immunotherapeutic anti-cancer activity and a favorable safety profile in early stage cervical cancer in a Phase 1/2 clinical trial.

"We expect that the combined company will have the financial resources and experienced leadership to accomplish our key near-term objectives: first, to initiate multiple late-stage clinical studies for our lead product candidate PDS0101; and second, to further advance our preclinical programs toward the clinic," PDS CEO Frank Bedu-Addo said in a statement.

What's Next
The deal is expected to close in the first quarter of 2019.

Following the consummation of the deal, the merged entity will function under the name PDS Biotechnology Corp., with the shares of the combined company to be listed on the Nasdaq under a new ticker symbol to be announced at a later date.

On the pipeline front, the combined company plans to initiate Phase 2b/3 clinical trials of PDS101 in HPV-associated cancers.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist